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Abstract: Parkinson’s disease (PD) affects millions around the world. The Braak hypothesis proposes
that in PD a pathologic agent may penetrate the nervous system via the olfactory bulb, gut, or both
and spreads throughout the nervous system. The agent is unknown, but several environmental
exposures have been associated with PD. Here, we summarize and examine the evidence for such
environmental exposures. We completed a comprehensive review of human epidemiologic studies
of pesticides, selected industrial compounds, and metals and their association with PD in PubMed
and Google Scholar until April 2016. Most studies show that rotenone and paraquat are linked to
increased PD risk and PD-like neuropathology. Organochlorines have also been linked to PD in
human and laboratory studies. Organophosphates and pyrethroids have limited but suggestive
human and animal data linked to PD. Iron has been found to be elevated in PD brain tissue but
the pathophysiological link is unclear. PD due to manganese has not been demonstrated, though
a parkinsonian syndrome associated with manganese is well-documented. Overall, the evidence
linking paraquat, rotenone, and organochlorines with PD appears strong; however, organophosphates,
pyrethroids, and polychlorinated biphenyls require further study. The studies related to metals do
not support an association with PD.
Keywords: environment and Parkinson’s disease; pesticides and Parkinson’s disease; toxins and
Parkinson’s disease
1. Introduction
Parkinson’s disease (PD) affects millions of people around the world and is a multi-organ
neurodegenerative process, affecting the nervous system, olfactory, and gastrointestinal tract. Patients’
motor features are characterized by bradykinesia with rigidity, resting tremor, or both caused by
a lack of the neurotransmitter dopamine from death of dopaminergic cells in the substantia nigra.
Involvement of non-dopaminergic neurons explains the significant non-motor features patients with
PD experience including depression, cognitive decline, sleep, and autonomic dysfunction due to
degeneration of serotonin, noradrenergic, and cholinergic neurons [1]. The etiology of PD has been
difficult to elucidate and appears to be a complex interplay of genetic and environmental factors [2].
Genetic factors are discussed elsewhere [3,4].
PD is the result of several levels of cellular dysfunction, including mitochondrial [5], lysososomal
and protease dysfunction [6,7], disorders of calcium homestasis [8], neuroinflammation [9], alpha
synuclein aggregation [10], and oxidative stress [11]. It is theorized that there is a “dual-hit” caused
by genetic predisposition and subsequent environmental factors interacting to create the cellular
dysfunction that causes PD. Furthermore, Braak and colleagues hypothesize that pathologic agents
penetrate the nervous system via the olfactory bulb, gut, or both and gradually spread to the nervous
system causing the non-motor and motor features of PD [12]. While the pathologic agent has yet to be
identified, several environmental exposures have been associated with PD.
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In this review, we summarize and examine human epidemiologic and case-control evidence
for individual environmental agents associated with PD. Primary human research articles from
peer-reviewed scientific journals were found from databases including PubMed and Google Scholar by
typing in search phrases such as “environment and Parkinson’s disease” and “case-control Parkinson’s”
with each of the environmental agents until April 2016 (Table 1). All case-control human studies that
examined specific agents (not groups of agents) with a sample size of cases greater than fifty were
included (see Table 1). We did not perform a comprehensive review of laboratory data and instead
selected relevant laboratory studies to enrich our discussion.
2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
We begin our discussion with MPTP, which is not a common environmental exposure but was
the first recognized agent that led to an animal model of Parkinsonism. MPTP was associated with
rapid-onset Parkinsonism when young drug abusers presented in Northern California with severe and
irreversible Parkinsonism responsive to dopamine therapy [13]. Subsequently, MPTP was identified
in synthetic heroin as the causative agent. MPTP crosses the blood brain barrier, and, in a two-step
reaction, converts to MPP+, which has a high affinity for dopamine transporters, explaining its selective
damage of dopaminergic neurons [14–16]. MPP damages neurons by inhibiting Complex 1 of the
electron transport chain [17]. Animal studies, including non-human primates and rodents, showed
MPTP produces striatal dopamine depletion with selective destruction of dopaminergic neurons in
the substantia nigra. Unlike in idiopathic PD however, other areas of the brain are remarkably spared
in MPTP-induced Parkinsonism including the locus ceruleus and other non-dopaminergic regions.
In addition, follow up of the drug addicts exposed to MPTP who developed Parkinsonism revealed
the stable, and not progressive, course of their symptoms, along with no Lewy Body pathology in
postmortem studies [18]. Interestingly, postmortem tissue analysis has also revealed active, ongoing
inflammation with the presence of microglia, extracellular melanin, and neurodegeneration years
after MPTP exposure, leading to the theory of “long-latency neurotoxicity” after agent exposure [18].
Oxidative stress and ongoing inflammation leading to nigral cell loss have been hypothesized as the
mechanism for the progressive and continued degeneration.
The study of MPTP has led to the development of the first animal models of the disorder and
continued interest in compounds that protect against neuroinflammation as potential treatments of
PD [19].
3. Pesticides
A frequent finding of epidemiologic studies is that PD is associated with farming as an occupation,
rural living, and well-water exposure. Subsequent research has found that pesticides indeed can cause
PD pathology in both animal models and humans.
Pesticides include an array of compounds designed to kill insects (insecticides), plants (herbicides),
and fungi (fungicides). Over five billion pounds of pesticides were used worldwide in 2007 [20].
Human exposure occurs through ingestion of pesticide residues in food, drinking water, and most
significantly, in occupational use including in agricultural field workers and workers in the pesticide
industry. Assessment of occupational human exposure and risk is extremely difficult given the
variability in protective measures during pesticide application, the dosage used, and the combination
of pesticides used. Exposure in non-occupational settings has been even more difficult to determine.
However, even with these limitations, many studies have found an association of PD with pesticides.
The first well-known study was in 1986, when Barbeau and colleagues evaluated PD prevalence in
a homogenous population in Quebec, Canada, and found high rates of prevalence in areas of pesticide
use [21]. This was followed by two case-control studies looking more closely at pesticide use, based on
subject interview, with no significant association found between pesticide use and PD [22,23]. Another
group chose to focus on young onset PD patients, as they hypothesized that those who presented with
PD early in life may have been exposed to a higher dose of the causative environmental agent. They
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found that PD was associated with insecticide or herbicide exposure, past residency in a fumigated
house, and rural residency at time of diagnosis [24]. The strengths of this study included validating the
questionnaire they used for patient self-exposure before using it on all subjects, as well as examining
the possibility of exposure in multiple forms of questions including asking about home fumigation.
Another interesting study used local agricultural office pesticide records to tailor a structured interview
for subjects, with cue cards showing the trade and common pesticide names, to more accurately
determine whether subjects were exposed to specific pesticides [25]. Despite the relative wealth of
specific pesticide data in this study, the overall use of pesticides was associated with PD, but the use
of individual pesticides was not. Three other studies in the 1990s relying on subject self-reported
pesticide use found no association between PD and pesticides [26–28], with another study finding a
marginal association [29]. In 2001, a study more carefully assessed the years of exposure to pesticides
and its association with Parkinsonism (as diagnostic data for PD was not sufficiently available) and
found higher prevalence of PD in the highest tertile of years of pesticide exposure, but not in lesser
durations, suggesting a dose-dependent relationship [30].
A seminal study examining duration of pesticide exposure was completed using data from the
Agricultural Health Study (AHS), a large American cohort study of over fifty thousand pesticide
applicators and their spouses, and found that PD was associated with higher cumulative days of
pesticide exposure at study enrollment [31]. This study also evaluated 26 individual pesticides and
their associations with PD, though most of these compounds were used by relatively few subjects (less
than fifty), finding only four compounds significantly associated with PD. The major strength of this
study is the large sample size, use of a cohort of pesticide applicators, and detailed associated data, but
a significant weakness is the reliance on subject self-report for both pesticide data and history of PD.
Another large United States cohort study found self-reported pesticide exposure to be significantly
associated with PD, while other occupational exposures including solvents were not [32].
Finally, a recent study that avoided the use of subject self-report and used geographic pesticide
exposure estimates (a similar approach to that used by other investigators, discussed further
below [33–36]) and Nebraska’s state-wide PD registry to find a significant association between PD and
certain pesticide ingredients that have not been previously well studied [37]. It is hoped that such novel
approaches, compared to the standard use of self-report, will be continued in future studies. Another
recent cohort study in the Netherlands found few weak associations between PD and exposure to
pesticides, but no association with exposure duration or cumulative exposure [38].
A limitation of these studies is that they often examine entire classes of pesticides and have limited
data on specific agents. Though the cumulative and perhaps synergistic effects of pesticides should be
explored, here we focus our review on a smaller number of studies that examine individual pesticide
compounds and their association with PD.
3.1. Rotenone
Rotenone is a plant-derived, naturally occurring pesticide that is commonly used as an insecticide
and to kill fish in reservoirs. Though it is organic and thus originally thought to be non-toxic to humans,
it has been found to be a mitochondrial toxin that inhibits Complex I of the electron transport chain [39]
with resulting progressive neurodegeneration of dopaminergic and non-dopaminergic neurons and
oxidative damage [40–42]. In rat models, administration of rotenone by daily intraperitoneal injection
produced bradykinesia, postural instability, and rigidity responsive to dopamine. Postmortem
rat studies found that nearly half of substantia nigra and striatal neurons were lost. In addition,
alpha-synuclein and polyubiquitin positive aggregates were observed in dopamine neurons in
the substantia nigra, similar to the Lewy Bodies found in PD [40,43] and in the enteric nervous
system [44,45]. Rotenone can also lead to phosphorylation and aggregation of tau and amyloid
proteins [46–48].
However, it is not always clear if the motor decline associated with rotenone is due solely to
dopaminergic dysfunction. Other animal studies of rotenone have found that, after low to high
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doses of rotenone administration, motor decline is not always associated with dopaminergic cell loss,
suggesting that rotenone may cause diffuse mitochondrial dysfunction in central non-dopaminergic as
well as peripheral cells outside of the central nervous system [49,50].
Now that rotenone-exposed animal models are reproducible and respected as a laboratory model
of PD, recent rotenone research focus is on new treatment. For example, a dietary phytocanniboid
given to rats before exposure to rotenone has been found to reduce oxidative damage, glial activation,
and dopaminergic cell loss [51]. Another study found that an adenosine receptor antagonist increased
midbrain dopamine concentrations and reduced the motor slowing in rotenone-exposed rats [52].
Human epidemiological studies show that PD developed more often in people who reported use
of rotenone compared with nonusers [53,54]. Among the most well known studies are those performed
in the large AHS cohort [53]. In addition, the Farming and Movement Evaluation study (FAME),
a small nested study within the AHS with only 69 cases and 237 controls, determined that rotenone
was associated with PD regardless of the use of protective gloves [55]. Despite the mixed laboratory
results, the supportive human epidemiologic studies combined with many supportive laboratory
studies suggest that rotenone is likely associated with PD.
3.2. Paraquat & Maneb
The herbicide paraquat is an oxidative stressor that, in several human case-control studies, was
associated with PD [31,34,35,53,56]. There has been great interest in paraquat due to its chemical
structure closely resembling the active metabolite of MPTP. Paraquat has often been studied with
maneb, a fungicide often used in the same geographical regions, and the evidence suggests these
pesticides likely have synergistic effects [57,58]. Maneb has been studied little individually, but, in one
early study, has been associated with Parkinsonism in humans [59]. Paraquat causes tissue damage
by setting off a redox cycle that generates toxic superoxide free radicals. A mimetic of superoxide
dismutase, an enzyme key in neutralizing superoxide free radicals, has been found to reduce the
mitochondrial damage and motor slowing cause by paraquat in Drosophila flies [60]. Furthermore,
in vivo animal studies indicate that paraquat stimulates glutamate efflux initiating excitotoxicity
mediated by reactive nitrogen species [61]. Similar studies have also demonstrated that paraquat
induces alpha-synuclein upregulation [62], aggregate formation, and microglial activation [63,64].
Systemic subchronic exposure to paraquat in mice induces dopaminergic neuronal cell death in the
basal ganglia, though overall dopamine levels remained unchanged [65]. However, higher doses
of chronic exposure did cause slow progressive degeneration of nigrostriatal neurons and delayed
reduction of dopaminergic neurotransmission [66], suggesting that paraquat may cause a “subclinical”
insult, and additional environmental or genetic factors may be required for PD to develop. In fact,
in another AHS epidemiologic study, deletions in the gene for a glutathione transferase, an enzyme
that provides cellular protection against oxidative stress, was associated with a higher risk of PD when
male subjects reported exposure to paraquat [67]. This area requires further investigation in humans
since this study was limited by a small sample size and exposure to multiple pesticides in addition to
paraquat. One more human study found that dopamine transporter susceptibility alleles and exposure
to maneb and paraquat led to higher PD risk [36], another example of the dual-hit phenomenon and
possible synergism. Strengths of this study included the use of geographic exposure estimates instead
of subject self-report, but the study was also limited by smaller subject sample sizes.
An alternative theory is that prenatal or early exposure to paraquat and maneb may disrupt
the development of the nigrostriatal dopamine system and enhance susceptibility to neurotoxicant
exposures later in life [68,69]. In support of this theory, the offspring of pregnant mice treated
with maneb had normal locomotor activity, but after subsequent treatment with paraquat, they had
significant reductions in locomotor activity and selective dopaminergic loss in the substantia nigra.
However, mice treated with paraquat prenatally and then maneb later in life did not show the same
changes, suggesting that the specificity and sequence of exposure may be important factors. Other
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studies have found synergy between paraquat and other compounds including MPTP [70] and the
organophosphate insecticide chlorpyrifos [71].
Beyond animal studies, human epidemiological studies have found that not only is paraquat
associated with PD occurrence, but the incidence of disease and the extent of paraquat exposure can
sometimes strongly correlate [56]. However, the human evidence has been mixed. In addition to
the negative pesticide studies described previously, a French case-control human study looking at
specific pesticide exposures found that paraquat was not associated with PD, but this was possibly
due to the study being performed in France, where paraquat is used at lower levels [72]. Like rotenone,
all research has not been entirely consistent, but overall several human case-control studies and
laboratory studies support an association between paraquat, with evidence of synergism with other
compounds such as maneb, and PD.
3.3. Organochlorines
Organochlorine pesticides are chlorinated hydrocarbons used extensively in the 1940s through
the 1970s in agriculture and mosquito control, and they have been banned in the United States
since they were suspected to be neurotoxicants [73] and have been associated with PD [72,74]. Two
compounds in particular, dieldrin and β Hexachlorocyclohexane (HCH), have been implicated as
associated with PD [75–78]. Both are lipophilic compounds that can be easily absorbed through
the skin, stored in fatty tissues for extended periods of time, and penetrate the blood brain barrier.
Dieldrin is thought to contribute to cell death in the substantia nigra by impairing mitochondrial
function and creating oxidative stress via reactive oxygen species [79,80] when the exposure is to
relatively high concentrations, but these effects are weak compared with those of rotenone, which
requires relatively low concentrations to cause such effects. However, an in vitro study did find
that dieldrin and HCH disrupt calcium homeostasis of dopaminergic cells even at low, nanomolar
concentrations [81], suggesting that further in vivo study should be performed. A case-control study
that analyzed serum samples for five organochlorine pesticides found only dieldrin to be associated
with a higher risk of PD [82]. In another case-control study, a genetic polymorphism associated with
a decreased ability to clear toxins from the brain and professional organochlorine exposure were
associated with increased PD risk [83]. Of note, postmortem studies of human brains have also found a
higher concentration of organochlorine compounds in PD brains, specifically in the striatum, compared
with the brains of patients without PD [84,85], while another postmortem study found organochlorine
levels were nonsignificantly associated with Lewy bodies [86].
3.4. Organophosphates
Organophosphates are pesticides that have known acute neurotoxic effects. However, chronic
professional and even household exposure may lead to increased PD risk [87,88]. In animals, neonatal
exposure to the chlorpyrifos led to long-term dopaminergic cell loss and microglial activation [89].
A case-control study found that higher rates of ambient organophosphate exposure were associated
with higher PD risk [33]. Interestingly, a common genetic variant of an enzyme important in detoxifying
organophosphates was also found to be associated with a greater than two-fold increased risk in PD
when carriers had been exposed to organophosphates compared with subjects without the variant
genotype [90]. The genetic variant has also been associated with PD in genetic analysis comparing
PD subjects to normal controls [91,92]. Many organophosphates, when entering the bloodstream, are
bioactivated into a toxic oxon form. Any oxon that escapes liver detoxification can be hydrolyzed
in the blood by serum paraoxonase (PON1) before it reaches the brain. The genetic variability
between individuals in PON1 activity may therefore lead to variable vulnerability to organophosphate
neurotoxic effects [90,92].
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3.5. Pyrethroids
Pyrethroids are a newer class of insectides often contained in household insecticides and mosquito
repellants. Animal studies have reported the ability of pyrethroids to indirectly increase dopamine
transporter-mediated dopamine uptake [93] and thus cause indirect apoptosis of dopaminergic
cells [94,95]. However, this area requires further study, as there is little specific human data besides the
general finding that pesticide exposure, including pyrethroids, is associated with PD [73].
4. Metals
Humans are exposed to metals through a variety of sources, including through diet and
occupational exposures such as manufacturing and welding. Many metals are essential minerals
important for human health. However, too much metal can be detrimental, and we have chosen to
focus on two metals in particular, iron and manganese, that have been associated with PD.
4.1. Iron
Iron has been found to be likely linked to the pathophysiology of PD in several laboratory
studies, but information of human exposure is scarce [4,96]. Some studies have found that increased
dietary iron is associated with PD [97,98], while studies on serum iron levels and their association
with PD have been conflicting [99–102]. Substantia nigra neurons contain neuromelanin that can
bind to iron and produce free radicals that in turn initiate lipid peroxidation and cell death [103].
Iron also promotes auto-oxidation of dopamine in substantia nigra neurons, releasing additional free
radicals [104]. Pathological studies have found increased levels of iron in the substantia nigra of PD
patients [105], and animal studies have shown that, in MPTP-induced Parkinsonism, iron chelation
can be therapeutic [106]. However, it remains unclear whether iron accumulation precedes injury of
substantia nigra neurons or occurs as a consequence of neuronal degeneration [103].
4.2. Manganese
Manganese is a basal ganglia toxin associated with Parkinsonism, but its association to idiopathic
PD remains controversial [107,108]. Manganese exposure can occur in working with steel, battery
manufacturing, intravenous synthetic drug use, and long-term parental nutrition and causes a distinct
syndrome with postural instability, a high-stepping gait characterized as a “cock-walk”, bradykinesia,
and rigidity that does not consistently respond to L-dopa therapy [108–112]. Such manganese-induced
Parkinsonism is distinct from idiopathic PD, which characteristically has bradykinesia and rigidity
that responds well to L-dopa with postural stability not presenting until later stages of the disease.
In manganese-induced Parkinsonism, MRI reveals T1 hyperintensity in the striatum and globus
pallidus and a normal dopamine transporter (DaT) scan, unlike in idiopathic PD when there are no
MRI changes and an abnormal DaT scan.
The mechanism of manganese neurotoxicity is degeneration of the globus pallidum mediated
by disruption of the mitochondria initiating both apoptosis and cell death via formation of highly
reactive oxygen species [113]. Manganese is rapidly taken up by the mitochondria where it promotes
calcium accumulation and inhibits oxidative phosphorylation, resulting in depletion of ATP [114–116].
In addition, manganese inhibits glutamate transport leading to increased levels of glutamate and thus
cytotoxicity [117]. In rats, early low-level exposure to manganese was associated with higher levels
of astrocytosis in the striatum as well as motor and cognitive impairment later in life, supporting
manganese as a potent neurotoxicant [118].
Despite the distinction between manganese neurotoxicity and idiopathic PD, there continues
to be interest in manganese exposure being a risk factor for PD with a few supportive studies.
A population-based case-control study found that a small percentage of subjects who reported over
twenty years of occupational exposure to manganese had a significantly higher risk of PD [119].
PD incidence was also found to be higher in urban counties with documented increased manganese
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industrial emissions [120] and in subjects who consumed higher amounts of dietary iron and
manganese [121]. An area of significant controversy is the association between PD and welding,
with reports suggesting that welding is associated with significant manganese exposure and may cause
Parkinsonism [122–125], with some investigators claiming that this Parkinsonism overlaps with PD
with no proof of true PD in these studies. Overall review of the evidence suggests that there is no clear
association between welding and PD [126], but manganese-induced Parkinsonism in welding may be
a true phenomenon difficult to disentangle from its impact in sporadic PD in view of litigations related
to job-related manganese exposure and PD.
5. Polychlorinated Biphenyls (PCBs)
Polychlorinated Biphenyls (PCBs) were produced and used commercially in industrial
manufacturing in the 1930s–1970s. They are lipophilic compounds that have been found in the
fatty tissues of fish and marine mammals [127]. In monkeys, PCB exposure produced a decrease
of dopamine in the brain [128]. The mechanism is thought to be the downregulation of dopamine
transporters that precedes damage to the dopamine striatal system [129]. In multiple human studies,
increased amounts of PCBs have been found in postmortem studies of PD brain tissue compared with
brain tissue unaffected by PD [84,130]. Humans who consumed higher amounts of whale were also
found to be at risk for PD [131]. However, other studies examining PCB exposure history and serum
levels of PCBs before subjects develop PD have found no association with PD [132,133]. Overall, the
human data is mixed. Though the commercial use of PCBs has been eliminated, their persistence
in the environment and the human body, with primary exposure through diet especially from the
consumption of marine mammals, make them a lasting threat to vulnerable populations such as
the Inuit.
6. Gaps in Knowledge
Several questions remain and require further study. While there has been significant work in
how environmental substances disrupt dopaminergic neurotransmission, more study is needed on
how these substances affect non-motor PD symptoms and disrupt related neurotransmitters including
noradrenaline, serotonin, and acetylcholine. Similarly, it would be critical to determine if there is an
association between prodromal PD [134] and exposure to currently used pesticides. More studies are
needed of the synergistic effects of multiple compounds as well as the interaction of pesticide exposure
with PD genetic predisposition. This will require large, multicenter, sufficiently powered studies
that use the same methodology. In addition, there is inadequate understanding on how toxins can
affect the microbiota or olfactory bulb and lead to alpha-synuclein aggregation, although we discussed
evidence of pesticides causing peripheral motor deficits and lung damage. We also need more objective
quantification of patient exposure, using geographic estimates, laboratory assays, and better tracking
by government agencies of pesticide and industrial compound use, because too much of our current
work relies on subject self-report, which is inevitably susceptible to bias and human error. Finally,
positive laboratory studies should be treated with measured skepticism, as varying techniques (in vitro
versus in vivo) and concentrations of toxins can produce contradictory and misleading results.
Clinicians, patients, and occupational health professionals need to better understand how to
apply the current knowledge to making clinical recommendations and lifestyle changes. We need
to understand how important a single environmental exposure is in relation to one’s genetic
predisposition and the infinite exposures one has in a lifetime, and how these factors can be modified
to prevent the development of PD. We need to understand how much exposure of a certain agent is
hazardous because most of the data we have is limited to robust and substantial exposures and not
lower rates of exposure, and whether the effects of toxicants can be synergistic. Ultimately, the most
intriguing question is whether laboratory studies of these compounds can lead to an accurate disease
model that could lead to the discovery of disease-modifying therapies. Environmental exposures and
PD is an exciting field for further study.
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Table 1. Summary of Case-Control Human Studies. Please see separate revised file in online submission.
Environmental Agent Authors Number of Cases/Controls Method Conclusions
Pesticides
Barbeau et al. 1987 [21] 5270 cases
Data analysis of geographic incidence of
PD, pesticide sales and mapping of
hydrographic regions
Pesticide use significantly correlated with PD prevalence (r = 0.967)
Stern et al. 1991 [23] 161/149 Chart review and Interview Exposure to pesticides were not associated with PD
Jimenez-Jimenez et al. 1992 [22] 128/256 Questionnaire and neurologicassessment PD not associated with history of pesticide exposure
Butterfield et al. 1993 [24] 63/68 Questionnaire and Interview Herbicide (OR 3.22) ** and insecticide (OR 5.75) *** exposure eachassociated with risk of PD
Hertzman et al. 1994 [25] 127/245 Interview and neurologic assessment
Occupational exposure to pesticides significantly associated with
risk of PD in male subjects OR 2.03 (95% CI 1.0, 4.12), with no
significant association found with specific pesticides
Morano et al. 1994 [28] 74/148 Questionnaire PD not associated with history of pesticide exposure, though wellwater drinking and rural living was.
Chan et al. 1998 [29] 215/313 Questionnaire, neurologic assessmentand genetic testing
Duration of pesticide exposure associated with marginally increased
risk of PD OR 1.05 (95% CI 1.01, 1.09) *
McCann et al. 1998 [26] 224/310 Interview and neurologic assessment PD not associated with history of pesticide exposure
Kuopio et al. 1999 [27] 123/145 Interview and neurologic assessment No significant association between pesticides and PD.
Engel et al. 2001 [30] Questionnaire andneurologic assessment
PR of 2.0 (95% CI 1.0, 4.2) ** for subjects in the highest tertile of years
of exposure to pesticides and a similarly increased, non-significant
PR was found for the middle tertile. No increased risks were found
associated with specific pesticides.
Ascherio et al. 2006 [32] 7864 Questionnaire and medicalrecord review
Exposure to pesticides had a 70% higher incidence of PD than in
those without exposure **
Kamel et al. 2007 [31] 161/55,931 Questionnaire and Interview PD associated with cumulative days of pesticide use at enrollment,OR 2.3 (95% CI 1.2, 4.5) **
Brouwer et al. 2015 [38] 609/4391 Questionnaire and cohort follow up ofPD incidence
Few significant associations between PD and occupational exposure
to pesticides
Wan et al. 2015 [37] 6557 cases
Use of state-wide PD registry and
geographic estimates of
pesticide exposure
No significant association with paraquat exposure, but with other
less studied pesticide ingredients
Rotenone
Tanner et al. 2011 [51] 110/358 Interview and neurologic assessment Rotenone exposure associated with PD, OR 2.5 (95% CI 1.3, 4.7) **
Dhillon et al. 2008 [52] 102/84 Questionnaire Report of past rotenone use was associated with PD, OR10.0 (95% CI 2.9, 34.3)
Furlong et al. 2015 [53] 69/237 Nested Case Control Study
Protective glove use modified association of paraquat and
permethrin with PD, paraquat OR 3.9 (95% CI 1.3, 11.7) * &
permethrin OR 4.3 (95% CI 1.2, 15.6) * but did not modify the
association with rotenone
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Table 1. Cont.
Environmental Agent Authors Number of Cases/Controls Method Conclusions
Paraquat
Liou et al. 1997 [54] 120/240 Interview and neurologic assessment Paraquat exposure associated with PD, OR 3.2 (95% CI 2.41, 4.31) **
Kamel et al. 2007 [31] 14/11,266 Questionnaire and Interview Paraquat associated with higher rate of prevalent PD,O.R. 1.8 (95% CI 1.0, 3.4)
Costello et al. 2009 [34] 268/341 Interview and geographic estimates ofambient paraquat exposure
Paraquat exposure associated with increased PD risk,
OR 2.27 (95% CI 0.91, 5.70)
Ritz et al. 2009 [36] 324/334 Genetic testing, neurologic assessmentand geographic exposure estimates
PD risk was increased in subjects who had one ore more dopamine
transporter susceptibility alleles with high exposure to paraquat and
maneb 1 allele OR 2.99; (95%CI 0.88, 10.2) & >2 alleles OR 4.53
(95% CI 1.7, 12.1)
Elbaz et al. 2009 [68] 224/557 Clinical evaluation and interview Paraquat exposure not associated with PD
Tanner et al. 2011 [51] 110/358 Interview and neurologic assessment Paraquat exposure associated with PD, OR 2.0 (95% CI 1.4, 4.7) **
Lee et al. 2012 [35] 357/754 Clinical evaluation, interview andpesticide exposure estimate
Paraquat exposure and history of traumatic brain injury associated
with PD risk OR 2.77 (95% CI 1.45, 5.29)
Goldman et al. 2012 [64] 87/343 Interview, neurologic assessment andDNA analysis
Men exposed to paraquat with functional glutathione S-transferase
M1 (GSTT1) genotype had lower risk of PD compared to men
exposed to paraquat lacking GSTT1
Maneb
Ferraz et al. 1988 [57] 50/19 Questionnaire andneurologic assessment Increased cogwheel rigidity associated with maneb exposure **
Wang et al. 2011 [56] 362/341
Interview and geographic estimates of
ambient paraquat, maneb and
ziram exposure
Combined exposure to all 3 pesticides associated with PD risk at
workplaces OR 3.09 (95% CI 1.69, 5.64) and residences OR 1.86 (95%
CI 1.09, 3.18) and combined exposure to ziram and paraquat at
workplaces associated with PD risk OR1.82 (95% CI 1.03,3.21)
Organochlorines
Seidler et al. 1996 [70] 380/755 Clinical evaluation and interview Association between PD and organochlorine exposureOR 5.8 (95% CI 1.1, 30.4)
Richardson et al. 2009 [71] 50/43 clinical evaluation and serum testing forlevels of organlchlorine pesticides
β-HCH was associated with higher likelihood of PD,
OR 4.39 (95% CI 1.67, 11.6) ***
Elbaz et al. 2009 [68] 224/557 Clinical evaluation and interview Organochlorine exposure associated with PD in menOR 2.2 (95% CI 1.1, 4.3)
Dutheil et al. 2010 [78] 207/482 Clinical evaluation, questionnaire andDNA analysis
Homozygous variants in the ABCB1 gene, responsible for clearing
xenobiotics, and reported organochlorine exposure was associated
with PD O.R 3.5 (95% CI 0.9, 14.5)
Weisskopf et al. 2010 [77] 349/101
Nested case-control study within
Finnish Mobile Clinic Health
Examination survey with analysis of
serum samples for dieldren
Dieldren was associated with OR 1.28 (95% CI 1.26, 3.02) **
Richardson et al. 2011 [71] 149/134 Clinical evaluation and serum testing forlevels of organochlorine pesticides
PD patients had higher serum levels of β-HCH than controls in
higher exposure cohort **, but in cohort with lower levels there was
no significant difference
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Table 1. Cont.
Environmental Agent Authors Number of Cases/Controls Method Conclusions
Organochlorines
Webster Ross et al. 2012 [81] 225
Postmortem study of organochlorine
levels in frozen occipital lobe samples
and identification of Lewy Bodies and
Lewy neurits
Insignificant associations between Lewy Body pathology and
presence of organochlorine compounds
Chhillar et al. 2013 [73] 70/75 Clinical evaluation and serum testing forlevels of organochlorine pesticides
β Hexachlorocyclohexane (HCH) and Dieldren levels were
significantly higher in PD *** with OR 2.56 (95% CI 1.68, 3.91) & 2.09
(95% CI 1.41, 3.11)
Steenland et al. 2014 [74] 89 Clinical evaluation and serum testing forlevels of organochlorine pesticides
Dieldrin was associated with a nonsignificant higher risk of tremor
at rest
Organophosphates
Akhmedova et al. 2001 [86] 117/207 DNA sample analysis Association between PD and PON1 gene polymorphism **
Carmine et al. 2002 [85] 114/127 DNA sample analysis Association between PD and PON1 gene polymorphism *
Firestone et al. 2005 [82] 250/388 Interview and chart review Organophosphate parathion associated with PD OR 8.08(95% CI 0.92, 70.85)
Manthripragada et al. 2010 [84] 351/363 Interview, estimate of ambient pesticideexposure and DNA sample analysis
Increased risk of PD with exposure to ambient organophosphates
and having common genetic variant in PON1
Wang et al. 2014 [33] 357/752 Interview and geographic estimates ofambient pesticide exposure
Exposure to ambient organophosphates associated with increased
odds of PD
Narayan et al. 2013 [83] 357/807 Interview and home pesticide ingredientdatabase review
Frequent use of household pesticides containing organophosphates
increased the odds of PD more strongly by 71%
OR 1.71 (95% CI 1.21, 2.41)
Iron
Logroscino et al. 2008 [91] 422/124,353 Questionnaire Dietary nonheme iron intake associated with PD, relative risk 1.27(95% Cl 0.92, 1.76) *
Miyake et al. 2011 [90] 249/368 Clinical evaluation and questionnaire Higher dietary intake of iron and other metals associated with lowerrisk of PD OR 0.33 (95% CI 0.13, 0.81) **
Farhoudi et al. 2012 [94] 50/50 Serum sample analysis Serum iron levels were not significantly different between PD andcontrol subjects
Zhao et al. 2013 [93] 238/302 Clinical evaluation and bloodsample analysis
Iron and selenium concentrations were significantly increased
in PD patients **
Kumudini et al. 2014 [92] 150/170 Clinical evaluation and bloodsample analysis
Plasma iron and copper levels were significantly elevated * in PD
subjects compared to controls, with no significant difference in
manganese and lead
Costa-Mallen et al. 2015 [95] 128/226 Serum iron, ferritin and haptoglobinphenotype testing PD cases has lower serum iron levels than controls
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Table 1. Cont.
Environmental Agent Authors Number of Cases/Controls Method Conclusions
Manganese
Gorell et al. 1997 [111] 144/464 Survey and estimates of occupationalmetal exposure
No significant elevated risk of PD with estimated manganese
exposure
Powers et al. 2003 [113] 250/388 Interview and nutrient intake estimates High intake of iron with manganeseassociated with increased PD risk
Park et al. 2004 [118] 105/129 Interview and questionnaire Occupations with high potential exposure to manganese notsignificantly associated with PD
Willis et al.. 2010 [112] NA
PD incidence calculated and compared
between counties with high or low
industrial release of manganese
PD incidence was greatest in counties with high manganese release
Polychlorinated
biphenyls (PCBs)
Steenland et al. 2005 [125] N/A Retrospective data analysis No overall increased incidence of PD in PCB exposed workers
Petersen et al. 2008 [123] 79/154 Clinical evaluation and serum and hairtesting
Whale meat consumption significantly associated with PD, OR 6.53
(95% CI 3.02, 14.14) ** serum PCBs not associated with PD
Weisskopf et al. 2012 [124] 101/349
Nested case-control study within
Finnish Mobile Clinic Health
Examination survey with analysis of
serum samples for PCBs
No significant association between increasing
PCB serum levels and PD
PD: Parkinson’s disease. OR = Odds ratio, CI = Confidence Interval, * p < 0.05, ** p < 0.01, *** p < 0.001, PCB = polychlorinated biphenyls.
Int. J. Environ. Res. Public Health 2016, 13, 881 12 of 19
7. Conclusions
Based on our detailed review of several original research studies, the evidence is strong that
environmental exposures play a role in the etiology of PD. Specifically, rotenone, paraquat, and
organochlorines have been well-documented in human epidemiological studies to be associated
with PD. Adding to the evidence, rotenone and paraquat often produce both the symptomatology
and pathology of PD in the laboratory, though importantly there are negative laboratory studies
and studies that show that rotenone and paraquat can cause peripheral injury that causes locomotor
deficits, as opposed to only central nervous system disease. In case-control studies, it is remarkable how
substantial exposure for long durations, related to farming as an occupation, suggests an association
with PD, but we have fewer data on lower rates of exposure. Organophosphates, pyrethroids,
and PCBs require further study since human data are limited. The studies related to metals have
overall been inconclusive or do not support an association with PD, and review of this literature
highlights the importance of separating PD and substance-induced Parkinsonism in evaluating
environmental exposures.
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